Logo image
Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement
Journal article   Open access   Peer reviewed

Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement

Michael L LeFevre and U.S. Preventive Services Task Force
Annals of internal medicine, Vol.161(11), pp.819-826
12/02/2014
DOI: 10.7326/M14-1884
PMID: 25200125
url
https://doi.org/10.7326/M14-1884View
Published (Version of record) Open Access

Abstract

Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy. The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed the maternal and fetal harms of low-dose aspirin during pregnancy. This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin. The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).
Pregnancy Risk Assessment Humans Cost of Illness Aspirin - administration & dosage Pre-Eclampsia - prevention & control Pre-Eclampsia - mortality Aspirin - adverse effects Platelet Aggregation Inhibitors - administration & dosage Biomedical Research Female Pregnancy Outcome Platelet Aggregation Inhibitors - adverse effects

Details

Metrics

Logo image